Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 11 Feb 2014 |
| Grant of Warrants to Employees in Genmab | 10 Feb 2014 |
| Arzerra® Fourth Quarter and Full Year 2013 Net Sales Figures | 5 Feb 2014 |
| Genmab’s Total Number of Voting Rights and Total Share Capital | 31 Jan 2014 |
| REGISTRATION OF CAPITAL INCREASE | 29 Jan 2014 |